Most cited papers from F-star (United Kingdom)

F-star (United Kingdom)

What are the most cited papers from F-star (United Kingdom)?

The most cited paper from F-star (United Kingdom) is "FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity" (Matthew Kraman, Mustapha Faroudi, Natalie L. Allen et al., 2020), with 113 citations. Next come "Systemic evaluation: a participative, multi-method approach" (71) and "FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models" (67).

Published TypeFieldAccessAuthors

Showing 33 of 33 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity Matthew Kraman, Mustapha Faroudi, Natalie L. Allen et al. · Clinical Cancer Research	16 Apr 2020	113
2	Systemic evaluation: a participative, multi-method approach Alan Boyd, T. Geerling, W. J. Gregory et al. · Journal of the Operational Research Society	6 Sep 2006	71
3	FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo et al. · Clinical Cancer Research	28 Apr 2020	67
4	CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement Miguel A. Gaspar, John Pravin, Leonor Nunes Rodrigues et al. · Cancer Immunology Research	9 Apr 2020	57
5	A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance Timothy Anthony Yap et al. · Clinical Cancer Research Open access	7 Nov 2022	53
6	Quality of intervention delivery in a cluster randomised controlled trial: a qualitative observational study with lessons for fidelity KAREN E. JAMES, Alan Quirk, Sue Patterson et al. · Trials Open access	17 Nov 2017	52
7	A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis Kin-Mei Leung, Sarah Batey, Robert J. Rowlands et al. · Molecular Therapy Open access	3 Aug 2015	34
8	Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics Katy L. Everett, Matthew Kraman, Francisca Wollerton et al. · Methods	9 Sep 2018	31
9	Mutant Lef1 controls Gata6 in sebaceous gland development and cancer Bénédicte Oulès, Emanuel Rognoni, Esther Hoste et al. · The EMBO Journal Open access	18 Mar 2019	27
10	Improving health care through community OR Michael Walsh, Tony Hostick · Journal of the Operational Research Society	8 Dec 2004	26
11	Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc Christoph Hasenhindl, Michael W. Traxlmayr, Gordana Wozniak‐Knopp et al. · Protein Engineering Design and Selection Open access	4 Sep 2013	21
12	A carbohydrate-binding affinity ligand for the specific enrichment of glycoproteins Chen Chen, Graziella El Khoury, Peiqing Zhang et al. · Journal of Chromatography A	20 Mar 2016	18
13	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one Andreas Lundqvist et al. · Journal for ImmunoTherapy of Cancer Open access1,762 authors	Nov 2016	11
14	Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models Brajesh Pratap Kaistha et al. · Cancer Biology & Therapy Open access	11 Jan 2024	10
15	Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report Maxwell Kroloff, Josefin-Beate Holz, Omer Stern et al. · Journal for ImmunoTherapy of Cancer Open access	Oct 2022	10
16	Biomarker Context-Of-Use: How Organizational Design Can Impact the Implementation of the Appropriate Biomarker Assay Strategy Kyra J. Cowan et al. · Bioanalysis	Jul 2022	9
17	IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy Charlotte J. Imianowski, Paula Kuo, Sarah K. Whiteside et al. · Cancer Research Communications Open access	12 Jul 2024	7
18	M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation Chunxiao Xu, Xueyuan Zhou, Lindsay Webb et al. · Cancer Immunology Research	13 Dec 2023	7
19	1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies K. Papadopoulos, Timothy Anthony Yap, Sarina Anne Piha-Paul et al. · Annals of Oncology Open access	Sep 2021	4
20	715 FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action Michelle Morrow, Mustapha Faroudi, Krishnendu Chakraborty et al. · Regular and Young Investigator Award Abstracts Conference paperOpen access	Nov 2020	4
21	Reverse immunology: From peptide sequence to tumor-killing human T-cell clones Christophe Vanhaver, Mónica Gordón‐Alonso, Alexandre Bayard et al. · Methods in enzymology on CD-ROM/Methods in enzymology Book chapterOpen access	17 Jun 2019	4
22	Antibodies as drugs—a Keystone Symposia report Jennifer Cable et al. · Annals of the New York Academy of Sciences Open access	16 Nov 2022	3
23	Pragmatic mAb lead molecule engineering from a developability perspective Bertie Chi, Geoffrey De Oliveira, Tom Gallagher et al. · Biotechnology and Bioengineering	29 Apr 2021	3
24	Improvement of Key Characteristics of Antibodies Neil Brewis · Learning materials in biosciences Book chapter	30 Nov 2020	2
25	Crowdsourcing to Enhance Insights from Satellite Observations Suvodeep Mazumdar, Stuart N. Wrigley, Fabio Ciravegna et al. · Earth systems data and models Book chapter	21 Dec 2017	2
26	The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4+ and CD8+ tumor-infiltrating lymphocytes Claire S. Reader, Wenjia Liao, Beatrice J. Potter-Landua et al. · Anti-Cancer Drugs Open access	17 Feb 2025	1
27	173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors G.A. De Velasco Oria, Elena Garralda, V. Moreno Garcia et al. · Immuno-Oncology Technology Open access	Dec 2022	1
28	165TiP A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies Elena Garralda, Ignacio Melero, Guillermo de Velasco et al. · Annals of Oncology Open access	Dec 2021	1
29	GNSSBio: Forest biomass retrieval based on GNSS ground receiver Antonio Mollfulleda, Francisco Martín, S. Paloscia et al. Conference paper	Jul 2017	1
30	Characterisation of AMD Versal FPGA Transceivers Under Heavy-Ion Radiation Alberto González Villafranca, Albert Ferrer Florit, Marti Farras Casas et al. Conference paper	2 Oct 2025	0
31	FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Designed for Optimal CD137 Engagement Resulting in Potent Conditional T-Cell Activity Matthew A. Lakins, Christel Séguy Veyssier, Jose M. Munoz-Olaya et al. · Current Cancer Drug Targets	9 Oct 2025	0
32	SpaceFibre IP Cores for Fast Adoption of Next-Gen FPGA Communication Architectures Alberto González Villafranca, Albert Ferrer Florit, Marti Farras Casas et al. Conference paper	Mar 2025	0
33	Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody Matthew A. Lakins, Jose M. Munoz-Olaya, D H Jones et al. · Annals of Oncology Open access	Dec 2018	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.